Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics.

Icon for Wiley Icon for PubMed Central Related Articles

Finding treatment-resistant depression in real-world data: How a data-driven approach compares with expert-based heuristics.

Depress Anxiety. 2018 03;35(3):220-228

Authors: Cepeda MS, Reps J, Fife D, Blacketer C, Stang P, Ryan P

BACKGROUND: Depression that does not respond to antidepressants is treatment-resistant depression (TRD). TRD definitions include assessments of treatment response, dose and duration, and implementing these definitions in claims databases can be challenging. We built a data-driven TRD definition and evaluated its performance.
METHODS: We included adults with depression, ≥1 antidepressant, and no diagnosis of mania, dementia, or psychosis. Subjects were stratified into those with and without proxy for TRD. Proxies for TRD were electroconvulsive therapy, deep brain, or vagus nerve stimulation. The index date for subjects with proxy for TRD was the procedure date, and for subjects without, the date of a randomly selected visit. We used three databases. We fit decision tree predictive models. We included number of distinct antidepressants, with and without adequate doses and duration, number of antipsychotics and psychotherapies, and expert-based definitions, 3, 6, and 12 months before index date. To assess performance, we calculated area under the curve (AUC) and transportability.
RESULTS: We analyzed 33,336 subjects with no proxy for TRD, and 3,566 with the proxy. Number of antidepressants and antipsychotics were selected in all periods. The best model was at 12 months with an AUC = 0.81. The rule transported well and states that a subject with ≥1 antipsychotic or ≥3 antidepressants in the last year has TRD. Applying this rule, 15.8% of subjects treated for depression had TRD.
CONCLUSION: The definition that best discriminates between subjects with and without TRD considers number of distinct antidepressants (≥3) or antipsychotics (≥1) in the last year.

PMID: 29244906 [PubMed – indexed for MEDLINE]

Source link

Related posts

Extending a Knowledge-Based System with Learning Capacity.


Brighterion wins Fortress Cyber Security Award


Connected Health Conference 2018: Balancing Technology and the Human Element


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World